Sales and Marketing

Showing 15 posts of 11526 posts found.

Telaprevir to be added to standard hep C therapy

March 27, 2011 Research and Development, Sales and Marketing hepatitis C, telaprevir

Telaprevir – currently being co-developed by Vertex, Johnson & Johnson and Mitsubishi Tanabe  – will become part of a standard …
Novartis Diagnostics Filiberto de Cal

Working Life: Novartis’ Filiberto de Cal

March 25, 2011 Business Services, Sales and Marketing Novartis, Working Life, recruitment

Filiberto de Cal is director of global marketing – new products at Novartis Diagnostics. Here he outlines his route into …

The Real-Time Rep Becomes a Reality – Changing the Rules of Engagement with Customers

March 24, 2011 Sales and Marketing

The Real-Time Rep Defined The Real-Time Rep, no longer a fictitious ideal, is a salesperson who is able to:
Pharma on Facebook

Digital Pharma: European pharma and social media

March 24, 2011 Medical Communications, Sales and Marketing Digital Pharma blog, Facebook, Twitter, social media, youtube

European pharma is increasingly running local social media initiatives as companies expand on their first, centrally-driven, uses of the technology.Details …

FDA delays decision on Novartis’ COPD drug

March 23, 2011 Sales and Marketing COPD, Novartis, Onbrez Breezhaler, QAB149, bronchodilator, chronic obstructive pulmonary disease, indacterol

The FDA has delayed its licence decision on Novartis’ once-daily COPD treatment QAB149 by three months. The review process will …

Eisai marine sponge derived cancer drug approved in Europe

March 23, 2011 Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate

Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …
GlaxoSmithKline office

GSK to fund schools science programme

March 23, 2011 Research and Development, Sales and Marketing GSK, GlaxoSmithKline, King's College, school science

GlaxoSmithKline has followed its pledge to refund the tuition fees of UK graduates it takes on with a less direct …
Novartis vaccines research

Novartis increases stake in Chinese vaccines firm

March 22, 2011 Sales and Marketing China, emerging markets, vaccines

Novartis has continued its expansion into developing markets with the acquisition of a majority stake in a Chinese vaccines company. …
Sanofi-Aventis HQ

Sanofi prostate cancer drug Jevtana approved in Europe

March 21, 2011 Sales and Marketing Jevtana, Sanofi-Aventis, TROPIC clinical trial, cabazitaxel, cancer drugs, chemotherapy, prostate cancer

Sanofi-Aventis’ new chemotherapy treatment Jevtana has followed up on its US approval last year by receiving the green light in …
Novartis headquarters

First oral MS pill approved in Europe

March 21, 2011 Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis

Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …

Guy Blomfield joins Alliance Medical Group

March 21, 2011 Sales and Marketing appointment, sales and marketing

European diagnostic imaging company Alliance Medical Group has appointed Guy Blomfield as group chief operating officer. He joins from from …

NHS Confederation: value-based pricing could increase NHS costs

March 18, 2011 Sales and Marketing NHS Confederation, PPRS, Pharmaceutical Price Regulation Scheme, UK drug pricing, VBP, value-based pricing

Government plans to introduce value-based pricing in the UK could increase the NHS drugs bill without improving the effectiveness of …
efpia_lif_richard_bergstrom

Richard Bergström takes DG role at EFPIA

March 18, 2011 Research and Development, Sales and Marketing Brian Ager, EFPIA, Richard Bergstrom, appointment, research and development, sales and marketing

European pharma industry association EFPIA has appointed Richard Bergström as its new director general. He takes over from Brian Ager, …

Novartis plans Q2 filing for blood cancer drug

March 17, 2011 Sales and Marketing COMFORT-II trial, INC424, Incyte, JAK, Janus kinase inhibitor, Novartis, blood cancer, cancer drug, myelofibrosis, ruxolitinib

Novartis will file ruxolitinib for worldwide regulatory approval in the second quarter after the cancer drug met its primary endpoint …
The Gateway to Local Adoption Series

Latest content